Conference Coverage

Monoclonal Antibodies "New Wave" in Passive Immunization

Published in AIDS Weekly, March 6th, 1995

Monoclonal antibodies (MAbs), which in the last decade revolutionized laboratory research, are now moving into clinical trials as experimental AIDS therapies.

New assay systems using resting T cells - the major target for HIV in vivo - show that wild-type HIV is far more sensitive to neutralization by MAbs than previously was thought possible, reported New York University researcher Susan Zolla-Pazner during a plenary address to the Nineteenth AIDS Clinical Trial Group (ACTG) Meeting, held February 18-22, 1995, in Washington, D.C.

"We have to reexamine the issue of whether antibodies can neutralize primary isolates," she said.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-03-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry